Developing Groundbreaking

Therapies in Cardiovascular

and Inflammatory Diseases

Founded on a Fundamentally New Therapeutic Modality

OMEICOS Therapeutics as a clinical stage company has translated pioneering scientific discoveries made at Max-Delbrück-Center in Berlin in collaboration with University of Texas Southwestern Medical Center into clinical development. We develop first-in-class small molecules targeting one of nature’s most important cell-protective pathways with treatment options in several indications.

A Complementary Leadership Team

OMEICOS’ is led by a dedicated team of highly skilled and experienced industry and research executives with all expertises for  clinical, scientific, operational and business aspects.

Robert Fischer

CEO/CSO
Co-Founder

Robert’s passion is to transform excellent science into novel treatments for diseases with high unmet medical need. Prior to taking the lead at OMEICOS, he worked as a clinical cardiologist at the Charité – Universitätsmedizin Berlin and led and participated in many clinical and preclinical research in activities together with the Max-Delbrück-Center for Molecular Medicine. Robert holds a PhD in cardiovascular physiology from the Freie Universität zu Berlin and received Board-certification for Internal Medicine.

Robert Fischer

CEO/CSO
Co-Founder

Robert’s passion is to transform excellent science into novel treatments for diseases with high unmet medical need. Prior to taking the lead at OMEICOS, he worked as a clinical cardiologist at the Charité – Universitätsmedizin Berlin and led and participated in many clinical and preclinical research in activities together with the Max-Delbrück-Center for Molecular Medicine. Robert holds a PhD in cardiovascular physiology from the Freie Universität zu Berlin and received Board-certification for Internal Medicine.

Simon Russell

CBO, Consultancy

Simon’s career began in R&D before gaining over 20 years’ experience in senior commercial and business roles in AstraZeneca, Novartis AG and biotech. Following his last role as Head of Strategic Marketing for Biologics at Novartis, he became CBO of Creabilis Ltd leading commercial, corporate and business development ultimately negotiating its sale to Sienna Biopharmaceuticals with its subsequent IPO on NASDAQ. He is a co-founder of a biotech emerging from the Basel incubator initiative. Dr Russell studied Chemistry at the University of Oxford and received a PhD from Southampton University.

Simon Russell

CBO, Consultancy

Simon’s career began in R&D before gaining over 20 years’ experience in senior commercial and business roles in AstraZeneca, Novartis AG and biotech. Following his last role as Head of Strategic Marketing for Biologics at Novartis, he became CBO of Creabilis Ltd leading commercial, corporate and business development ultimately negotiating its sale to Sienna Biopharmaceuticals with its subsequent IPO on NASDAQ. He is a co-founder of a biotech emerging from the Basel incubator initiative. Dr Russell studied Chemistry at the University of Oxford and received a PhD from Southampton University.

Karen Uhlmann

Vice President Operations & IP
Co-Founder

Karen has more than 20 years’ experience in IP Asset Management, building and running organizations and being instrumental in raising funds, executing all different routes of commercialization. She holds a Master and a PhD in Biology from Freie Universität zu Berlin and Humboldt-Universität zu Berlin, and has earned a business degree from the Chamber of Commerce Berlin..

Karen Uhlmann

Vice President Operations & IP
Co-Founder

Karen has more than 20 years’ experience in IP Asset Management, building and running organizations and being instrumental in raising funds, executing all different routes of commercialization. She holds a Master and a PhD in Biology from Freie Universität zu Berlin and Humboldt-Universität zu Berlin, and has earned a business degree from the Chamber of Commerce Berlin..

Edita Bade

Head of Finance
& Controlling

Edita has gained more than 20 years of experience in various Finance, Controlling & Project Leader roles across a broad range of industries. Prior to joining OMEICOS, she supported the leadership team of an international Real Estate development company with the valuation and long-term value development projections of real estate opportunities, due diligence and acquisition/sales of these assets.

Edita Bade

Head of Finance
& Controlling

Edita has gained more than 20 years of experience in various Finance, Controlling & Project Leader roles across a broad range of industries. Prior to joining OMEICOS, she supported the leadership team of an international Real Estate development company with the valuation and long-term value development projections of real estate opportunities, due diligence and acquisition/sales of these assets.

Henk Streefkerk

Clinical Development, Consultancy

Henk, MD PhD, joined OMEICOS as Consultant ‘Clinical Development’ in September 2020. Henk is a medical doctor with a PhD in neurosurgery from University of Utrecht. He held multiple medical roles in large companies (Organon, Novartis) and biotech (Actelion, PIQUR), in translational medicine, safety, and clinical development in cardiovascular, oncology, and orphan diseases. Most recently, he was CMO of an Oncology Biotech in Basel. Henk supports OMEICOS in the overall clinical development of OMT-28.

Henk Streefkerk

Clinical Development, Consultancy

Henk, MD PhD, joined OMEICOS as Consultant ‘Clinical Development’ in September 2020. Henk is a medical doctor with a PhD in neurosurgery from University of Utrecht. He held multiple medical roles in large companies (Organon, Novartis) and biotech (Actelion, PIQUR), in translational medicine, safety, and clinical development in cardiovascular, oncology, and orphan diseases. Most recently, he was CMO of an Oncology Biotech in Basel. Henk supports OMEICOS in the overall clinical development of OMT-28.

Markus Henrich

Medicinal Chemistry and CMC, Consultancy

Markus has more than 20 years of experience in various roles in the pharmaceutical industry, amongst them Executive Director Drug Discovery and Development at Merz Pharmaceuticals GmbH. In his current role as management consultant he constantly supports OMEICOS in the field of drug discovery and development. Areas of special expertise are innovation productivity and CMC.

Markus Henrich

Medicinal Chemistry and CMC, Consultancy

Markus has more than 20 years of experience in various roles in the pharmaceutical industry, amongst them Executive Director Drug Discovery and Development at Merz Pharmaceuticals GmbH. In his current role as management consultant he constantly supports OMEICOS in the field of drug discovery and development. Areas of special expertise are innovation productivity and CMC.

An Experienced Board Supporting OMEICOS

OMEICOS’ Supervisory Board consists of professionally qualified members with many years of experience in the biotechnology and pharmaceutical industries as well as academic research in the relevant sectors for the company.

Supervisory Board

Bernhard Kirschbaum

Chairman

Bernhard Kirschbaum studied biochemistry and physiological chemistry at the University of Konstanz and received his PhD in 1989. He moved on to work at the Rockefeller University and the Pasteur Institute before making a career in the pharmaceutical industry where he covered a broad range of technological and disease areas. In his most recent position, Dr. Kirschbaum served as head of Global Research and Early Development at Merck Serono where he was a member of the board.

Bernhard Kirschbaum

Chairman

Bernhard Kirschbaum studied biochemistry and physiological chemistry at the University of Konstanz and received his PhD in 1989. He moved on to work at the Rockefeller University and the Pasteur Institute before making a career in the pharmaceutical industry where he covered a broad range of technological and disease areas. In his most recent position, Dr. Kirschbaum served as head of Global Research and Early Development at Merck Serono where he was a member of the board.

Christian Schneider

Christian Schneider, Managing Partner of Vesalius Biocapital, has been a venture capital executive for 20 years. He gained extensive experience in the areas of diagnostics, medtech, and therapeutics in the corporate life science and venture capital industry. Previously he held positions of increasing responsibility at Boehringer Mannheim, Centocor, and Johnson&Johnson. As a managing partner of VC firm PolyTechnos, he was responsible for OncoMethylome (IPO, 2006), Devgen (IPO, 2005) and Jerini (IPO, 2005). He was support partner for Addex (IPO, 2007) and BiPar (USD 500m sale to Sanofi-Aventis, 2009). He joined Vesalius in 2008 and is responsible for the portfolio companies Skyline (write-off), Activaero (EUR 130m sale to Vectura, 2014), Ventaleon, OMEICOS, Humedics and Mecuris where he serves on the boards. Dr. Schneider holds a doctorate degree in veterinary medicine (1992) and a PhD in immunology (1995), both from the University of Munich, Germany, and an MBA with focus on healthcare administration from Penn State University, Pennsylvania (1999).

Christian Schneider

Christian Schneider, Managing Partner of Vesalius Biocapital, has been a venture capital executive for 20 years. He gained extensive experience in the areas of diagnostics, medtech, and therapeutics in the corporate life science and venture capital industry. Previously he held positions of increasing responsibility at Boehringer Mannheim, Centocor, and Johnson&Johnson. As a managing partner of VC firm PolyTechnos, he was responsible for OncoMethylome (IPO, 2006), Devgen (IPO, 2005) and Jerini (IPO, 2005). He was support partner for Addex (IPO, 2007) and BiPar (USD 500m sale to Sanofi-Aventis, 2009). He joined Vesalius in 2008 and is responsible for the portfolio companies Skyline (write-off), Activaero (EUR 130m sale to Vectura, 2014), Ventaleon, OMEICOS, Humedics and Mecuris where he serves on the boards. Dr. Schneider holds a doctorate degree in veterinary medicine (1992) and a PhD in immunology (1995), both from the University of Munich, Germany, and an MBA with focus on healthcare administration from Penn State University, Pennsylvania (1999).

Peter Seiler

Head of Treasury Vice President SMS GmbH




Peter Seiler

Head of Treasury Vice President SMS GmbH




Taro Inaba

Taro Inaba is Founder and Managing Partner at Remiges Ventures. He has over 29 years of business experience including 19 years in start-up financing and company creation. At Remiges, Taro is engaged in technology sourcing, company creation, leading negotiation for investments and serving as director for seven of the Remiges’ portfolio companies. Prior to establishing Remiges Ventures, he spent 13 years at divisions of Mitsui & Co., Ltd. engaged in venture investment activities where he built and managed the biopharma investment team and investment portfolio. He served as President & CEO of Mitsui & Co. Venture Partners in Menlo Park, California from 2008 to 2009. Taro holds a B.E. in Polymer Chemistry, Kyoto University and MBA from European University. Taro is a CFA charter holder.

Taro Inaba

Taro Inaba is Founder and Managing Partner at Remiges Ventures. He has over 29 years of business experience including 19 years in start-up financing and company creation. At Remiges, Taro is engaged in technology sourcing, company creation, leading negotiation for investments and serving as director for seven of the Remiges’ portfolio companies. Prior to establishing Remiges Ventures, he spent 13 years at divisions of Mitsui & Co., Ltd. engaged in venture investment activities where he built and managed the biopharma investment team and investment portfolio. He served as President & CEO of Mitsui & Co. Venture Partners in Menlo Park, California from 2008 to 2009. Taro holds a B.E. in Polymer Chemistry, Kyoto University and MBA from European University. Taro is a CFA charter holder.

Wolf-Hagen Schunck

Wolf-Hagen Schunck is biochemist at the Max Delbrück Center for Molecular Medicine in Berlin-Buch. He has over 30 years of research experience in the field of cytochrome P450 (CYP)-derived bioactive lipid mediators. Dr. Schunck’s laboratory identified 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) laying the scientific basis for the foundation of OMEICOS. In collaboration with fellow co-founder Dr. John R. Falck, he developed robust synthetic analogues for in vivo administration. The current work of Dr. Schunck is focused on further elucidating the cellular and molecular mechanisms underlying the unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS.

Wolf-Hagen Schunck

Wolf-Hagen Schunck is biochemist at the Max Delbrück Center for Molecular Medicine in Berlin-Buch. He has over 30 years of research experience in the field of cytochrome P450 (CYP)-derived bioactive lipid mediators. Dr. Schunck’s laboratory identified 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) laying the scientific basis for the foundation of OMEICOS. In collaboration with fellow co-founder Dr. John R. Falck, he developed robust synthetic analogues for in vivo administration. The current work of Dr. Schunck is focused on further elucidating the cellular and molecular mechanisms underlying the unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS.

Rapid Progress Into and Through the Clinic

Since its foundation, OMEICOS has made steady progress towards its goal of developing its core therapeutic approach into and through clinical trials. Thanks to a very lean and efficient drug development organization, the company was able to bring its lead asset OMT-28 into proof-of-concept and dose finding trials in less than 6 years.

2023

2022

2020

Phase IIa

APRIL 2023

OMEICOS receives allowance from authorities for its Phase II study in PMD patients

DECEMBER 2022

OMEICOS announces to advance its lead program, OMT-28, into a first Phase II study in Primary Mitochondrial Disease patients

JULY 2022

OMEICOS secures financing for the expansion of its clinical development activities

OCTOBER 2020

OMEICOS initiates the planning of 2 new Phase 2 studies with OMT-28 in CV inflammation and mitochondrial diseases

SEPTEMBER 2020

OMEICOS completes Phase 2 clinical study with OMT-28 and progresses 2 more candidates into pre-clinical development

2019

2018

Phase II

APRIL 2019

OMEICOS initiates Phase 2 clinical trial with OMT-28 focusing on maintenance of sinus rhythm in patients suffering from persistent Atrial Fibrillation

NOVEMBER 2018

OMEICOS announces the closing of a EUR 17 million Series C financing led by new investor Forbion

2017

Phase I

JULY 2018

OMEICOS announces compelling first-in-human data on OMT-28 and prepares Phase 2 trial in Atrial Fibrillation

OCTOBER 2017

OMEICOS establishes a US subsidiary to manage future North American operations and secures second tranche of Series B with REMIGES Ventures as new investor

MARCH 2017

OMEICOS initiates Phase 1 clinical trial with OMT-28 and closes first tranche of a Series B with EUR 8.3 million

2015

2014

Pre-Clinical

April 2015

OMEICOS closes Series A round with EUR 6.2 million to take OMT-28 towards clinical trials

JULY 2014

OMEICOS elects OMT-28 as lead compound after completion of a comprehensive pre-clinical assessment

2013

Discovery

JUNE 2013

OMEICOS was spun-out of the Max Delbrück Center for Molecular Medicine to explore the therapeutic potential of stabilized version of epoxyeicosanoids